A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)-Reference-Cited by-同舟云学术

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)

Published:2005-01 Issue:1 Volume:16 Page:124-131
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ballova V.,Rüffer J.-U.,Haverkamp H.,Pfistner B.,Müller-Hermelink H.K.,Dühmke E.,Worst P.,Wilhelmy M.,Naumann R.,Hentrich M.,Eich H.T.,Josting A.,Löffler M.,Diehl V.,Engert A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/16/1/124/435761/mdi023.pdf

Reference40 articles.

1. Effect of age on therapeutic response and survival in advanced Hodgkin's disease;Peterson;Cancer Treat Rep,1982

2. Hodgkin's disease in patients over sixty years old;Austin-Seymour;Ann Intern Med,1984

3. Survival of the older patients compared with the younger patient with Hodgkin's disease;Walker;Cancer,1990

4. Björkholm M, Biberfeld P et al. Prognostic factors in Hodgkin's disease with special reference to age;Wendelin;Cancer,1984

5. Age and Hodgkin's disease: the impact of competing risks and possibility salvage therapy on long term survival: an ECOG study;Bennett;Leuk Res,1993

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aging Kairos: treating older Hodgkin patients;Blood;2024-03-14

2. Hodgkin lymphoma treatment for older persons in the modern era;Hematology;2023-12-08

3. ‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—A multicentre, retrospective study;British Journal of Haematology;2023-06-25

4. Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting;Future Oncology;2023-06

5. Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity;Frontiers in Oncology;2023-01-13